Closer than ever
WntResearch has applied for their phase II trials regarding proof-of-concept for the FOXT-5 compound. Hence, WntResearch is closer than ever to start the trials with up to 180 colon cancer patients – trials that are expected to commence in the fourth quarter of 2018.
WE expect that the actual commencement of the trials with the first patients enrolled will have a positive effect on the share price. We reiterate our expectations to the share price of SEK 20-25 the next 6 months and SEK 25-30 within the next 12 months.
Share price development last 12 months
SHARE PRICE EXPECTATIONS
CURRENT SHARE PRICE: SEK 19,22
0-6 MONTHS: SEK 20-25 (+0-30%)
6-12 MONTHS: SEK 25-30 (+30-56%)